Effects of Dietary Nutrients on Liver and Adipose Tissue Metabolism
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
In health,adipose tissue stores fat from the diet. If the fat tissue stops storing dietary fat then this increases the chance of it being stored in the liver, which is related to increased risk of heart disease and type 2 diabetes. It has been suggested that having a diet high in sugars or certain fats, may cause the fat tissue and liver to change how they function; we would like to investigate this in detail.
Condition or disease
Other: Overconsumption of specific dietary nutrient
This research aims to investigate how the overconsumption of specific macronutrients may effect adipose tissue and liver metabolism and function. Liver and heart fat content and adipose tissue and liver metabolism fasting and postprandial lipid metabolism will be assessed before and after the specific dietary intervention.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Participant is willing and able to give informed consent for participation in the study.
Male or Female, aged ≥18 or ≤65 years.
Body Mass Index ≥19 ≤35 kg/m2
No medical condition or relevant drug therapy known to affect liver or adipose tissue metabolism.
Weight stable for the previous 3 months
Patient is unwilling or unable to give informed consent for participation in the study
A blood haemoglobin <135mg/dL for men and <120mg/dL for women
Donated (or lost) ≥250 ml of blood in the previous two months.
On a weight loss diet or have decreased their body weight by >5% in the previous 3 months.
Have increased their body weight by >5% in the previous 3 months.
Any metabolic condition or relevant drug therapy
History of alcoholism or a greater than recommended alcohol intake (>30 g of alcohol daily for men and >20 g of alcohol daily for women)
History of albumin allergy
Pregnant or nursing mothers
Women who are taking any contraceptive agent or device including oral contraceptives, hormone replacement therapy (HRT) or who have used these within the last 12 months
History of severe claustrophobia
Presence of metallic implants, pacemaker, or are unwilling to remove any piercings
History of an eating disorder or any other psychological condition that may affect the participants ability to adhere to study intervention/experimental diets.
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Following completion of the study, all individual data obtained from participants may potentially be shared with other researchers, both here in the United Kingdom and abroad, in appropriate circumstances. If data is to be shared with other researchers, it will be done so under fully anonymised conditions.
Layout table for additional information
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Additional relevant MeSH terms:
Layout table for MeSH terms
Physiological Effects of Drugs